Core Points - Voyageur Pharmaceuticals Ltd. has received significant investor support through the exercise of 14,708,013 share purchase warrants for gross proceeds of $1,470,801, including 1,120,000 warrants exercised by the Executive Vice-President [1] - The company aims to become a leader in the radiology drug market by vertically integrating the barium and iodine contrast markets [3][4] - Voyageur has developed five barium contrast products that have received Health Canada licenses [4] - The company plans to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers [5] - Voyageur owns a 100% interest in the Frances Creek barium sulphate project, which is believed to produce higher quality imaging products compared to synthetic alternatives [6] - The company's vision is to control all primary input costs, ensuring quality and cost efficiency in the production of radiology contrast media [7]